Actos Franchise Drives Takeda's Pharmaceutical Sales Growth
This article was originally published in PharmAsia News
Executive Summary
Higher sales of Actos (pioglitazone) products were the prime driver behind a 7.7 percent increase in Takeda's pharmaceuticals segment for the nine months ending Dec. 31, 2007, compared with the same period in 2006, the company reported Jan. 31.